Joseph Panetta introduces the conference and we discuss the state of biotech in California's numerous biotech hubs.

He discusses some of the key theme of the conference including obesity, IgG, ATTR cardiomyopathy, and more.

He describes what made him excited about the company, and why he views diabetic retinopathy as potentially a bigger opportunity than wet AMD

Ying Huang talks about Friday's CHMP positive opinion and the upcoming FDA advisory committee meeting, and highlight's Legend's pipeline.

Craig Tooman describes Silence's two lead programs targeting Lp(a) and polycythemia vera, as well as the company's broader platform.

On the heels of a historic recent approval for the class, Lynn Seely describes the science behind TIL therapies.

Kevin Parker describes how Cartography has been building an antigen map over previous years.

Paul Matteis gives his take on biotech's start to the year and comments on Alnylam, Biogen, Vertex, KalVista, Denali, Acadia, and more.

Raphael Townshend describes how the company has used AI and large language models to understand the structure and function of RNA.

Cognito CEO Brent Vaughan introduces the company's device and walks us through the randomized P2 study.

Daphne Koller describes the platform insitro has been building since it was founded in 2018.

The event leveraged the substantial biotech industry and investor presence that exists in the Greater Bay Area around Stanford.

Carolyn Bertozzi introduces Firefly and explains the idea behind combining the science of antibody-drug conjugates with protein degraders

David Nierengarten gives his take on biotech and discusses Blueprint Medicines, G1 Therapeutics, Y-mAbs, Fusion Pharma, and more.

Arnon Rosenthal walks us through the idea of the immune system playing a central role in neuro-degeneration

Jason Lettmann describes how he believes having an inactive Fc domain makes all the difference in the CD47 space.

Marshall Fordyce describes the rationale of targeting both BAFF and APRIL as a B-cell modulator for IgAN.

Amanda Finck describes her interest in science and how it has led her to work in the Center for Cellular Immunotherapies at UPenn.

Prime Medicine CEO Keith Gottesdiener describes the advantages he sees in prime editing.